{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:00:31Z","timestamp":1775847631842,"version":"3.50.1"},"reference-count":0,"publisher":"Korean Ophthalmological Society","issue":"4","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ekjo.org"],"crossmark-restriction":true},"short-container-title":["Korean J Ophthalmol"],"published-print":{"date-parts":[[2025,8,5]]},"abstract":"<jats:p>Purpose: To evaluate the effectiveness of 0.125% atropine eye drops in controlling myopia progression by analyzing 1-year follow-up data through a multicenter retrospective study in South Korea.Methods: A retrospective chart review was conducted across five centers, including 121 myopic children (aged 4\u201311 years) treated with 0.125% atropine between January 2021 and December 2023. An equal number of age-, sex-, axial length (AL)-, and spherical equivalent (SE)-matched untreated individuals (control group) were included. Baseline and follow-up data at 6 and 12 months included visual acuity, autorefraction, AL measurement (IOLMaster 700), and fundus examination. The primary outcome measures were changes in SE and AL compared to controls.Results: Age, SE, and AL in the treatment group at baseline were 7.5 \u00b1 1.5 years (range, 4 to 11), \u20133.07 \u00b1 1.65 diopters (D; range, \u20130.25 to \u20135.88 D), and 24.39 \u00b1 0.85 mm (range, 22.19 to 26.94 mm), respectively, and these parameters showed no statistical differences compared to the matched controls. SE after 1-year treatment was less myopic in the treatment group (\u20133.42 \u00b1 1.72 D vs. \u20133.94 \u00b1 1.92 D, &lt;i&gt;p&lt;\/i&gt; = 0.019). Similarly, AL was significantly shorter in treatment group compared to the control group (24.65 \u00b1 0.88 mm vs. 24.88 \u00b1 0.80 mm, &lt;i&gt;p&lt;\/i&gt; = 0.031). The SE change from baseline was \u20130.33 \u00b1 0.73 D in the treatment group versus \u20130.91 \u00b1 1.01 D in the control group (&lt;i&gt;p&lt;\/i&gt; &lt; 0.001). AL increased by 0.25 \u00b1 0.32 mm in the treatment group, significantly less than 0.49 \u00b1 0.24 mm increase in the control group (&lt;i&gt;p&lt;\/i&gt; &lt; 0.001). Baseline AL and mean keratometry showed no correlation with AL progression (all &lt;i&gt;p&lt;\/i&gt; &gt; 0.05).Conclusions: The use of 0.125% atropine eye drops significantly reduced myopia progression, with approximately 50% reduction in AL elongation compared to controls. Given its effectiveness and variable compliance, 0.125% atropine eye drops may serve as a viable alternative to low-dose atropine for myopia control.<\/jats:p>","DOI":"10.3341\/kjo.2025.0039","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:49:52Z","timestamp":1751244592000},"page":"323-329","update-policy":"https:\/\/doi.org\/10.3341\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic Effect of Topical 0.125% Atropine in South Korean Myopic Children: A Real-World Experience"],"prefix":"10.3341","volume":"39","author":[{"given":"Dae Hee","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Ah","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Kyung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ungsoo Samuel","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae Jung","family":"Paik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1893","container-title":["Korean Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.ekjo.org\/upload\/pdf\/kjo-2025-0039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2025.0039","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.ekjo.org\/upload\/pdf\/kjo-2025-0039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:41:18Z","timestamp":1754440878000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2025.0039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.3341\/kjo.2025.0039","relation":{},"ISSN":["1011-8942","2092-9382"],"issn-type":[{"value":"1011-8942","type":"print"},{"value":"2092-9382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"2025-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-30","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-05","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}